AbbVie Might Be Most Affected By FDA’s HCV Drug Safety Warning
A US FDA warning of serious liver injuries in hepatitis C patients treated with combo pills from AbbVie, Gilead and Merck may impact AbbVie's Mavyret most, since it's one of the company's top sellers.
You may also be interested in...
While it works on merging with Allergan, AbbVie is tracking biosimilar sales erosion to Humira, the promising launch of Skyrizi and the growth of Imbruvica and Venclexta. It is terminating a Phase II study of a tau-targeting antibody and worried about aspects of the Senate drug pricing bill.
Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.
FDA imposes boxed warning on labels for hepatitis C drugs in response to reports of hepatitis B reactivation, including fatal cases.